Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.03%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $3.65 per share when it actually produced earnings of $3.80, delivering a surprise of 4.11%. Over the last four quarters, ...

财务业绩 - 第三季度收入为742亿美元，同比增长10.9%[2] - 第三季度GAAP每股收益为2.42美元，调整后每股收益为3.34美元[6] - 调整后每股收益指引范围上调至13.55美元至13.65美元[3] - 公司第二季度收入为742.41亿美元，同比增长10.9%[37] - 毛利率为3.25%，同比增长6.5%[38] - 销售、分销和管理费用占收入比重为1.86%，同比增加6.1%[39] - 第二季度净利润为4.84亿美元，同比增长0.8%[42] - 每股摊薄收益为2.42美元，同比增长3.0%[43] - 公司第三季度收入为2149.08亿美元，同比增长11.2%[48] - 第三季度毛利率为3.45%，同比增长10.6%[49] - 第三季度销售、分销和管理费用占收入比重为1.94%，同比增加6.5%[50] - 第三季度净利润为15.06亿美元，同比增长8.0%[53] - 第三季度每股摊薄收益为7.49美元，同比增长10.1%[54] - 公司GAAP营业收入为74.24亿美元，同比增长10.9%[85] - 公司GAAP毛利率为3.45%，调整后非GAAP毛利率为3.39%[74] - 公司GAAP营业费用率为2.50%，调整后非GAAP营业费用率为2.09%[74] - 公司GAAP营业利润率为0.95%，调整后非GAAP营业利润率为1.30%[74] - 公司GAAP净利润为15.06亿美元，同比增长8.0%，调整后非GAAP净利润为20.95亿美元，同比增长12.0%[72] - 公司GAAP每股摊薄收益为7.49美元，调整后非GAAP每股摊薄收益为10.42美元，同比增长14.1%[72] - 公司总营收同比增长11.2%，其中美国医疗解决方案业务增长12.1%，国际医疗解决方案业务增长4.0%[96] - 总营业利润同比增长12.4%，其中美国医疗解决方案业务增长13.9%，国际医疗解决方案业务增长6.7%[98] - 美国医疗解决方案业务毛利率为2.48%，同比下降0.04个百分点；国际医疗解决方案业务毛利率为11.73%，同比上升0.16个百分点[100][101] - 美国医疗解决方案业务营业利润率为1.16%，同比上升0.02个百分点；国际医疗解决方案业务营业利润率为2.63%，同比上升0.06个百分点[100][101] - 公司GAAP口径下毛利率为3.45%，同比下降0.02个百分点；非GAAP口径下毛利率为3.39%，同比下降0.08个百分点[103][105] - 公司GAAP口径下营业利润率为0.95%，同比下降0.01个百分点；非GAAP口径下营业利润率为1.30%，同比上升0.01个百分点[103][105] 现金流和资产负债 - 公司现金及现金等价物余额为33.06亿美元，较上年同期增加7.14亿美元[109] - 公司应收账款净额为240.51亿美元，较上年同期增加30.40亿美元[109] - 公司存货为183.02亿美元，较上年同期增加8.47亿美元[109] 非GAAP指标 - 调整后税前收入是一个非GAAP财务指标，排除了一些非经常性和非经营性项目[128] - 调整后所得税费用是一个非GAAP财务指标，排除了一些非经常性和非经营性项目[129] - 调整后有效税率是一个非GAAP财务指标，不包括一些非经常性和非经营性项目[130] - 调整后归属于公司的净收入是一个非GAAP财务指标，排除了一些非经常性和非经营性项目[131] - 调整后每股摊薄收益是一个非GAAP财务指标，排除了一些非经常性和非经营性项目的影响[132] - 调整后自由现金流是一个非GAAP财务指标，排除了一些非经常性和非经营性现金流[133] 业务分部表现 - 美国医疗保健解决方案分部收入增长12.2%[25] - 国际医疗保健解决方案分部收入持平，但按固定汇率计算增长5.8%[26] - 公司美国医疗保健解决方案分部营业收入为671.92亿美元，同比增长12.2%[85] - 公司美国医疗保健解决方案分部营业利润为6.35亿美元，同比增长9.9%[87] - 公司国际医疗保健解决方案分部营业收入为70.52亿美元，同比增长0.1%[85] - 公司国际医疗保健解决方案分部营业利润为1.87亿美元，同比下降4.1%[87] 财务指引 - 预计2024财年收入增长约12%，其中美国医疗保健解决方案收入增长12%至13%[29] - 预计2024财年调整后每股收益为13.55美元至13.65美元[29] - 预计2024财年调整后自由现金流为25亿美元至30亿美元[29] - 公司提供了一些非GAAP财务指标的2024财年指引，排除了一些非经常性和非经营性项目[135] 其他 - 宣布派发每股0.51美元的季度现金股利[30] - 公司将于7月31日召开电话会议讨论业绩[31] - 公司提供了一些以"不变汇率"计算的财务数据，以消除汇率波动的影响[134]

The second-quarter 2024 earnings season has just begun for the Medical sector (one of the 16 broad Zacks sectors within the Zacks Industry classification), with several MedTech players ready to release their quarterly results. The latest Earnings Trends indicates that 16.9% of the companies in the Medical sector, constituting nearly 33.8% of the sector's market capitalization, reported earnings until Jul 24. All reported companies beat on their respective earnings and revenues. Earnings increased 4.2% year ...

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days. Valu ...

In the last reported quarter, the company delivered an earnings surprise of 4.11%. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 6.12%. The Zacks Consensus Estimate for revenues is pegged at $73.58 billion, indicating an improvement of 9.9% from the top line reported in the prior-year quarter. The consensus mark for earnings is pinned at $3.18 per share, implying growth of 8.9% from the year-ago quarter's recorded number. Sustained strong growth in spec ...

This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.40%. For Cencora, estimates have been trending higher, thanks in part to this earnings surprise history. And when you The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related ...

文章核心观点 - 英国MHRA批准LYTENAVA™(bevacizumab gamma)用于治疗湿性AMD [1][3][9] - LYTENAVA™是首个获得欧盟和英国市场授权的贝伐珠单抗眼科制剂 [9][12] - 公司计划于2025年第一季度在欧盟和英国推出LYTENAVA™ [4][5] - 公司与Cencora公司建立战略合作伙伴关系,支持LYTENAVA™在英国和欧盟的商业化推广 [5][6][7] 根据目录分别总结 公司信息 - Outlook Therapeutics是一家专注于ONS-5010/LYTENAVA™(贝伐珠单抗)开发和商业化的生物制药公司 [12] - 在美国,ONS-5010/LYTENAVA™正在进行湿性AMD的非劣效性研究,如果成功可能重新提交BLA申请 [10][13] - 如果在美国获批,ONS-5010/LYTENAVA™将成为首个获批用于视网膜疾病(包括湿性AMD)的贝伐珠单抗眼科制剂 [13] 产品信息 - LYTENAVA™(bevacizumab gamma)是一种重组人源化单克隆抗体,可选择性高亲和力结合所有人源VEGF亚型,中和其生物学活性 [11] - LYTENAVA™获得欧盟和英国市场授权,用于治疗湿性AMD [9] 商业化合作 - 公司与Cencora公司建立战略合作伙伴关系,Cencora将提供全面的商业化支持,包括药物警戒、监管事务、质量管理、市场准入支持、进口、第三方物流、分销和现场解决方案 [5][6][7] - 这种合作和一体化方法旨在支持LYTENAVA™的市场准入和高效分销,使所有利益相关方(包括视网膜专科医生、医疗服务提供商和患者)受益 [6]

Cencora's shares have risen 11% year to date compared with the industry's growth of 4.1%. the S&P 500 Index has increased 15.2% in the same period. Per a CNN article, the recent Supreme Court ruling invalidated the $6 billion settlement related to the primary alleged entity in opioid abuse litigation, Purdue Pharma, which would have shielded its owner, the Sackler family, from future financial claims. Moreover, four states opted not to join the national settlement in 2021 and were able to continue their leg ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment Update Since my last publication on Cencora (NYSE:COR) shares have continued to advance and now trade 13% higher. This marks a substantial gain from the original buy thesis I presented on COR in 2023. Analysts in a Bernstein-Societe Generale rated COR a high-quality stock with high ROIC trading at sensible valuations in a recent analysis. This is exactly the sentiment I have held with COR since day on, and this has not changed. Earning ...

The rally in the company's share price can be attributed to the robust growth in the company's U.S. Healthcare Solutions segment. The optimism led by a solid second-quarter fiscal 2024 performance and robust business potential are expected to contribute further. Cencora exited second-quarter fiscal 2024 with decent results. The company witnessed solid top-line and bottom-line performances in the reported quarter, which is likely to have aided in the price growth. In the fiscal second quarter, Cencora's U.S. ...